Medtronic plc (NYSE:MDT) and Tenet Healthcare Corporation (NYSE:THC) offer investors two very different healthcare growth stories. Medtronic’s (NYSE:MDT) thesis rests on whether a new generation of medical devices can produce a durable turnaround across its enormous portfolio. Tenet (NYSE:THC), meanwhile, is generating stronger earnings by improving hospital profitability and focusing its ambulatory business on higher-acuity procedures.
The comparison ultimately comes down to whether investors prefer Medtronic’s (NYSE:MDT) innovation-led recovery or Tenet’s (NYSE:THC) stronger operating leverage.
Bull Case
Medtronic (NYSE:MDT) reported its highest annual revenue growth in a decade in its fiscal Q4 and full-year 2026 results, suggesting that years of investment in faster-growing technologies are beginning to produce meaningful results. Growth opportunities including Affera, Symplicity, Hugo, Altaviva, and Stealth AXiS give the company several potential drivers rather than leaving its recovery dependent on a single product.
Cardiac Ablation Solutions has emerged as a particularly important contributor. Revenue increased 78% globally, including 124% growth in the United States, as newer products strengthened Medtronic’s (NYSE:MDT) position in the expanding cardiac-ablation market. The company is also investing in innovation and acquisitions, including targeted investments in intracardiac echocardiography catheter technology.
The breadth of Medtronic’s (NYSE:MDT) pipeline supports the possibility that its recent acceleration can spread across more of the portfolio. Improving sentiment toward the wider medical-technology sector could provide an additional catalyst if the company maintains its execution. BTIG has argued that MedTech may be stabilizing following a period of underperformance, although company-specific results will ultimately matter more than broader sector sentiment.
Tenet’s (NYSE:THC) latest earnings present a more immediate growth story. Adjusted diluted EPS increased 52.2% year over year to $6.12, while net operating revenue rose 6.8% to $5.63 billion. Ambulatory revenue increased 9.3% to approximately $1.39 billion, while hospital revenue grew 6% to around $4.20 billion.
More importantly, Tenet’s (NYSE:THC) improvement was not confined to its faster-growing ambulatory platform. Hospital adjusted EBITDA margin expanded from 15.6% to 18% despite an unfavourable payer mix. Hospitals are operationally complex and labour-intensive, making that degree of margin expansion particularly significant. The combination of higher revenue and wider margins indicates that Tenet (NYSE:THC) is generating operating leverage rather than simply becoming a larger business.
Bear Case
Medtronic (NYSE:MDT) still needs to demonstrate that its turnaround is sustainable. Management has spent several years attempting to accelerate growth, while much of the latest momentum remains concentrated in a limited number of faster-growing product categories. Competition also remains intense in cardiovascular devices and robotic surgery, particularly from Boston Scientific and Intuitive Surgical. If growth fails to broaden across the portfolio, Medtronic’s (NYSE:MDT) scale could continue to constrain its overall expansion rate.
Tenet (NYSE:THC) faces a different concern: its ambulatory business is producing stronger financial results despite performing fewer procedures. USPI’s same-facility systemwide net patient service revenue increased 5%, while surgical cases declined 1.2% and net revenue per case rose 6.3%, reflecting the company’s focus on higher-acuity procedures. Higher revenue per case can offset weaker volumes, but it may not sustain the same growth rate indefinitely. If procedure volumes remain negative while revenue-per-case growth normalizes, USPI’s earnings momentum could slow.
Payer mix presents another risk, as management attributed part of the unfavorable payer mix to lower exchange admissions. Tenet (NYSE:THC) absorbed that pressure during the quarter through higher hospital revenue, increased acuity, and disciplined expense management, but if payer-mix weakness continues, it could weigh on revenue quality and profitability.
Conclusion
Tenet (NYSE:THC) currently offers the stronger earnings-growth story, supported by broad-based revenue gains, hospital margin expansion, and operating leverage. However, weaker surgical volumes and payer-mix deterioration make that growth more sensitive to execution.
Medtronic’s (NYSE:MDT) turnaround is less advanced, but its diversified portfolio and expanding pipeline provide multiple potential long-term growth drivers. Therefore, Tenet (NYSE:THC) appears better positioned for investors prioritizing current earnings momentum, while Medtronic (NYSE:MDT) may offer the more diversified long-term opportunity if its recent product-led acceleration becomes broader and more durable.
